Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
August 20 2024 - 4:05PM
Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the
"Company"), an eyecare technology company focused on developing and
commercializing innovative, interventional technologies that
elevate the standard of care, today announced that it will present
at the upcoming Morgan Stanley Global Healthcare Conference, in New
York, NY.
Sight Sciences’ management is scheduled to
present on Wednesday, September 4, 2024, at 1:50 pm PT / 4:50 pm
ET. Interested parties may access a live and archived webcast of
the fireside chat on the “Investors” section of the company’s
website at: investors.sightsciences.com.
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative and interventional solutions intended to
transform care and improve patients’ lives. Using minimally
invasive or non-invasive approaches to target the underlying causes
of the world’s most prevalent eye diseases, Sight Sciences seeks to
create more effective treatment paradigms that enhance patient care
and supplant conventional outdated approaches. The Company’s OMNI®
Surgical System is an implant-free glaucoma surgery technology (i)
indicated in the United States to reduce intraocular pressure in
adult patients with primary open-angle glaucoma; and (ii) CE Marked
for the catheterization and transluminal viscodilation of Schlemm’s
canal and cutting of the trabecular meshwork to reduce intraocular
pressure in adult patients with open-angle glaucoma. Glaucoma is
the world’s leading cause of irreversible blindness. The SION®
Surgical Instrument is a bladeless, manually operated device used
in ophthalmic surgical procedures to excise trabecular meshwork.
The Company’s TearCare® System is 510(k) cleared in the United
States for the application of localized heat therapy in adult
patients with evaporative dry eye disease due to meibomian gland
dysfunction (“MGD”), enabling clearance of gland obstructions by
physicians to address the leading cause of dry eye disease. Visit
www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo,
TearCare, SmartHub and SmartLids are trademarks of Sight Sciences
registered in the United States. OMNI and SION are trademarks of
Sight Sciences registered in the United States, European Union and
other territories.
© 2024 Sight Sciences. All rights reserved.
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Media contact:
pr@SightSciences.com
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Oct 2023 to Oct 2024